<DOC>
	<DOCNO>NCT02394795</DOCNO>
	<brief_summary>The purpose study verify efficacy mFOLFOX6 + panitumumab combination therapy mFOLFOX6 + bevacizumab combination therapy first-line treatment chemotherapy-naive patient KRAS/NRAS wild-type , incurable/unresectable , advanced/recurrent colorectal cancer .</brief_summary>
	<brief_title>Panitumumab RAS , DIagnostically-useful Gene Mutation mCRC ) .</brief_title>
	<detailed_description>The purpose study verify efficacy mFOLFOX6 + panitumumab combination therapy mFOLFOX6 + bevacizumab combination therapy first-line treatment chemotherapy-naive patient KRAS/NRAS wild-type , incurable/unresectable , advanced/recurrent colorectal cancer . This study enroll total 800 participant ( 400 per group ) . Patients randomize either mFOLFOX6 + panitumumab arm ( Group P ) mFOLFOX6 + bevacizumab arm ( Group B ) 1:1 ratio time registration . Group P Group B treatment regimen show administered every two week , follow dose , schedule route administration . Group P ; mFOLFOX6 + panitumumab combination therapy , every two week OXA : 85 mg/m2/day 1 LV : 200 mg/m2/day 15-FU iv : 400 mg/m2/day 1 5-FU civ : 2400 mg/m2/day 1-3 panitumumab : 6 mg/kg Group B ; mFOLFOX6 + bevacizumab combination therapy , every two week OXA : 85 mg/m2/day 1 LV : 200 mg/m2/day 1 5-FU iv : 400 mg/m2/day 1 5-FU civ : 2400 mg/m2/day 1-3 bevacizumab : 5 mg/kg/ This trial conduct multicenter schedule 12 month whole administration period . As additional study main study investigate biomarkers exploratory may predictors Panitumumab Bevacizumab efficacy , use tumor issue blood sample treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Investigator subinvestigator judge candidate understand clinical trial comply protocol . 2 . Patients give write consent take part study detail explanation study prior enrollment 3 . Aged ≥20 &lt; 80 year time inform consent 4 . Patients unresectable adenocarcinoma originate large intestine ( exclude carcinoma appendix anal canal cancer ) 5 . Patients lesion ( ) evaluate . It essential evaluate tumor accord RECIST ver . 1.1 . 6 . Patients receive chemotherapy colorectal cancer . Patients experience relapse 24 week ( 168 day ) final dose perioperative adjuvant chemotherapy fluoropyrimidine agent may enrol . Patients receive perioperative adjuvant chemotherapy include oxaliplatin exclude . 7 . Patients classify KRAS/NRAS wildtype KRAS/NRAS testing . KRAS/NRAS test perform use vitro diagnostic list National Health Insurance . Patients mutation codon show consider wild type . KRAS : EXON2 ( codon 12 , 13 ) , EXON3 ( codon 59 , 61 ) , EXON4 ( codon 117 , 146 ) NRAS：EXON2 ( codon 12 , 13 ) , EXON3 ( codon 59 , 61 ) , EXON4 ( codon 117 , 146 ) ( 8 ) Patients satisfy follow criterion major organ function test perform within 14 day prior enrollment 1 . Neutrophil count great 1.5×103/µL 2 . Platelet count great than1.0×104/µL 3 . Hemoglobin great 9.0 g/dL 4 . Total bilirubin le 2.0 mg/dL 5 . AST great than100 IU/L ( less 200 IU/L liver metastasis present ) 6 . ALT great 100 IU/L ( less 200 IU/L liver metastasis present ) 7 . Serum creatinine less than1.5 mg/dL 8 . PTINR &lt; 1.5 ( &lt; 3.0 patient treated oral warfarin ) 9 . Satisfies least one condition ( ) Urine protein ( dip stick method ) less 2+ ( ii ) UPC ( urine protein creatinine ) ratio less than1.0 ( iii ) Urinary protein less 1000mg/ 24hours ( 9 ) ECOG performance status ( PS ) 0 1 ( 10 ) Life expectancy ≥ 3 month ( 90 day ) enrollment 1 . Radiotherapy receive within 4 week ( 28 day ) prior enrollment 2 . Known brain metastasis strongly suspect brain metastasis 3 . Synchronous cancer metachronous cancer diseasefree period le 5 year ( exclude colorectal cancer ) exclude mucosal cancer cure possibly cure regional resection ( esophageal , stomach , cervical cancer , nonmelanoma skin cancer , bladder cancer , etc. ) . 4 . Body cavity fluid require treatment ( pleural effusion , ascites , pericardial effusion , etc . ) 5 . Patients want use contraception prevent pregnancy , woman pregnant breastfeeding , test positive pregnancy 6 . Nonhealing surgical wound ( exclude implant venous reservoir ) 7 . Active hemorrhage require blood transfusion 8 . Disease require systemic steroid treatment ( exclude topical steroid ) 9 . The patient place colonic stent 10 . Intestinal resection within 4 week prior enrollment colostomy within 2 week prior enrollmentt 11 . History obvious extensive CT finding interstitial pulmonary disease ( interstitial pneumonia , pulmonary fibrosis , etc . ) 12 . Patients unstable angina , myocardial infarction , cerebral hemorrhage , arterial thromboembolism cerebral infarction , history desease le 24 week ( 168 day ) registration ( except lacunar infarction asymptomatic ) 13 . Serious drug hypersensitivity 14 . Local systemic active infection require treatment , fever indicate infection 15 . NYHA class II high heart failure serious heart disease 16 . Intestinal paralysis , gastrointestinal obstruction , uncontrollable diarrhoea ( incapacitate symptom despite adequate treatment ) 17 . Poorly control hypertension 18 . Poorly control diabetes mellitus 19 . Active hepatitis B 20 . Known HIV infection 21 . Peripheral neuropathy great Grade 2 CTCAE ( Japanese edition JCOG version 4.03 ) 22 . Other patient judge investigator subinvestigator ineligible enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metastatic colorectal cancer , Panitumumab , mFOLFOX6 , Bevacizumab</keyword>
</DOC>